Thus, the distinction between HER2 0+ and HER2 1+ is gaining relevance, as is the concept of “HER2-low” breast cancer, encompassing those HER2 1+ and HER2 2+ tumors without HER2 amplification [5,12]. This evidence concerns the gene ERBB2 and breast cancer.